AstraZeneca COVID-19 vaccine

Regulatory Information

Regulatory approval of COVID-19 AstraZeneca vaccine

PGD for COVID-19 AstraZeneca vaccine

Patient Group Direction for COVID-19 AstraZeneca vaccine


Legal Mechanisms for adminstration of the covid-19 vaccines

National Protocol

National Protocol for Astra Zeneca COVID-19 Vaccine


Transporting the AstraZeneca COVID 19 vaccine from PCN designated sites to end user locations , patients homes and within the PCN grouping


Dealing with delivery issues associated with the Covid-19 vaccines  


Receiving and storing the AstraZeneca COVID-19 vaccine

Stock Control

Stocktaking and reconciliation of the AstraZeneca COVID-19 Vaccine 


Ordering the AstraZeneca COVID-19 Vaccine by PCN designated sites


Preparing the AstraZeneca COVID-19 Vaccine


Advising individuals with allergies on their suitability for AstraZeneca C0vid 19 vaccine 



Disposing of AstraZeneca COVID-19 Vaccine at PCN designated sites –


Use of the covid-19 vaccine AstraZeneca to vaccinate housebound patients 11th Jan 2021

Position statement for vaccination of care home residents using COVID 19 vaccine AstraZeneca

The contents of this statement – recommends when planning vaccination sessions for care homes a primary care lead, pharmacist and lead GP at PCN designated site should complete an assessment to identify or understand risk factors associated with the transfer of the vaccine for the administration of remaining care home residents.